Briquilimab is under clinical development by Jasper Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Briquilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Briquilimab overview
Briquilimab (AMG-191) is under development for the treatment of fanconi anemia, myelodysplastic syndrome, severe combined immunodeficiency, acute myeloid leukemia, sickle cell disease, chronic granulomatous disease (CGD), chronic inducible urticaria (CIndU), passive systemic anaphylaxis, cockroach allergen induced allergic asthma, atopic dermatitis and chronic spontaneous urticaria (CSU). The drug candidate acts by targeting stem cell growth factor receptor Kit. It is a humanized anti-c-Kit monoclonal antibody. It is administered through intravenous route and subcutaneous route.
It was also under development for the treatment of Gaucher disease type 1 and inflammatory diseases such as idiopathic pulmonary fibrosis (IPF).
Jasper Therapeutics overview
Jasper Therapeutics is a biotechnology company that develops antibodies for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate-risk myelodysplastic syndromes (MDS). It also operates as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). It develops and commercializes stem cell engineering for expanded use of stem cell transplantation. The company pipeline products are JSP191 is in clinical development that clears hematopoietic stem cells from bone marrow. It also offers engineered hematopoietic stem cells(eHSCs) platform to address the limitations of transplant grafts and unlock the potential of stem cells. Jasper Therapeutics is headquartered in ReedWood, California, the US
For a complete picture of Briquilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
